- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.3: 11 residues within 4Å:- Chain A: N.37, S.171, P.174, V.216, L.223, N.224, N.338, G.340, V.406, S.407
- Ligands: NAG.31
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.11: 11 residues within 4Å:- Chain E: S.171, E.173, P.174, V.216, L.223, N.224, N.338, G.340, V.406, S.407
- Ligands: NAG.45
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:S.171, E:S.171
NAG-NAG-BMA-MAN.17: 10 residues within 4Å:- Chain I: S.171, P.174, V.216, L.223, N.224, N.338, G.340, V.406, S.407
- Ligands: NAG.59
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:G.340
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.4: 11 residues within 4Å:- Chain A: V.104, T.105, N.118, Y.135, L.137, K.267, D.282
- Chain M: K.54, T.55, E.56, G.57
3 PLIP interactions:2 interactions with chain A, 1 interactions with chain M- Hydrophobic interactions: A:Y.135
- Hydrogen bonds: A:K.267, M:T.55, M:T.55, M:G.57
NAG-NAG-BMA.20: 13 residues within 4Å:- Chain I: T.98, S.120, F.121, N.122, R.131, W.150, T.151
- Chain M: D.106, D.117, Y.119, R.121
- Chain N: T.57, G.58
3 PLIP interactions:2 interactions with chain M, 1 interactions with chain I- Hydrophobic interactions: M:Y.119
- Hydrogen bonds: M:Y.119, I:W.150
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN.5: 22 residues within 4Å:- Chain A: T.98, Q.100, S.120, N.122
- Chain E: N.129
- Chain M: R.50, T.100, G.101, E.103, Y.105, Y.118, F.120, D.122
- Chain N: I.32, Y.33, Y.37, L.47, Y.50, G.51, S.53, S.54, Y.92
4 PLIP interactions:2 interactions with chain M, 2 interactions with chain N- Hydrogen bonds: M:E.103, M:Y.118, N:S.54, N:S.54, N:S.53, N:S.53
- 3 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-FUC.6: 4 residues within 4Å:- Chain B: N.107, S.109, E.110
- Chain C: S.107
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:S.109, B:S.109
NAG-FUC.13: 5 residues within 4Å:- Chain F: N.105, R.106, N.107, E.110
- Ligands: NAG.50
3 PLIP interactions:3 interactions with chain F- Hydrogen bonds: F:N.105, F:N.107, F:N.107
NAG-FUC.21: 5 residues within 4Å:- Chain J: N.105, N.107, S.109, E.110
- Chain K: S.107
1 PLIP interactions:1 interactions with chain J- Hydrogen bonds: J:N.105
- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-FUC.7: 5 residues within 4Å:- Chain B: N.100, S.102, W.103, Y.127, I.130
2 PLIP interactions:2 interactions with chain B- Hydrophobic interactions: B:Y.127
- Hydrogen bonds: B:S.102
NAG-NAG-FUC.14: 5 residues within 4Å:- Chain F: N.100, S.102, W.103, Y.127, I.130
2 PLIP interactions:2 interactions with chain F- Hydrophobic interactions: F:Y.127
- Hydrogen bonds: F:S.102
NAG-NAG-FUC.22: 5 residues within 4Å:- Chain J: N.100, S.102, W.103, Y.127, I.130
1 PLIP interactions:1 interactions with chain J- Hydrophobic interactions: J:Y.127
- 41 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.23: 3 residues within 4Å:- Chain A: E.57, N.58
- Chain B: S.17
Ligand excluded by PLIPNAG.24: 4 residues within 4Å:- Chain A: N.196, I.234, S.236, H.313
Ligand excluded by PLIPNAG.25: 1 residues within 4Å:- Chain A: N.107
Ligand excluded by PLIPNAG.26: 1 residues within 4Å:- Chain A: N.316
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain A: N.238, N.241
Ligand excluded by PLIPNAG.28: 4 residues within 4Å:- Chain A: Q.324, S.349, N.353
- Ligands: NAG-NAG.1
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain A: K.296, N.300, W.356
Ligand excluded by PLIPNAG.30: 4 residues within 4Å:- Chain A: Q.255, N.257, N.293, S.295
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain A: N.224, P.253, N.408
- Ligands: NAG-NAG-BMA-MAN.3
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain A: N.263, I.284, V.402
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain A: R.154, N.159, T.160
- Chain E: R.270
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain A: N.103, K.117
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain B: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain B: N.114
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain E: E.57, N.58
- Chain F: S.17
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain E: N.196, T.198, S.236, H.313
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain E: N.107
Ligand excluded by PLIPNAG.40: 1 residues within 4Å:- Chain E: N.316
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain E: N.238, T.240, N.241
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain E: S.349, N.353
- Ligands: NAG-NAG.9
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain E: K.296, N.300, W.356
Ligand excluded by PLIPNAG.44: 5 residues within 4Å:- Chain E: Q.255, N.257, N.293, S.295, R.404
Ligand excluded by PLIPNAG.45: 5 residues within 4Å:- Chain E: N.224, V.406, S.407, N.408
- Ligands: NAG-NAG-BMA-MAN.11
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain E: N.263, I.284, V.402
Ligand excluded by PLIPNAG.47: 5 residues within 4Å:- Chain E: V.144, R.154, N.159, T.160
- Chain I: R.270
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain E: N.103, R.113, W.150
Ligand excluded by PLIPNAG.49: 5 residues within 4Å:- Chain F: K.122, E.123, S.125, N.126, Y.127
Ligand excluded by PLIPNAG.50: 5 residues within 4Å:- Chain F: S.109, E.110, D.113, N.114
- Ligands: NAG-FUC.13
Ligand excluded by PLIPNAG.51: 4 residues within 4Å:- Chain I: E.57, N.58
- Chain J: G.16, S.17
Ligand excluded by PLIPNAG.52: 4 residues within 4Å:- Chain I: N.196, T.198, S.236, H.313
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain I: N.106, N.107
Ligand excluded by PLIPNAG.54: 1 residues within 4Å:- Chain I: N.316
Ligand excluded by PLIPNAG.55: 3 residues within 4Å:- Chain I: N.238, T.240, N.241
Ligand excluded by PLIPNAG.56: 4 residues within 4Å:- Chain I: Q.324, S.349, N.353
- Ligands: NAG-NAG.15
Ligand excluded by PLIPNAG.57: 2 residues within 4Å:- Chain I: N.300, W.356
Ligand excluded by PLIPNAG.58: 5 residues within 4Å:- Chain I: Q.255, N.257, N.293, S.295, R.404
Ligand excluded by PLIPNAG.59: 5 residues within 4Å:- Chain I: N.224, V.406, S.407, N.408
- Ligands: NAG-NAG-BMA-MAN.17
Ligand excluded by PLIPNAG.60: 3 residues within 4Å:- Chain I: N.263, I.284, V.402
Ligand excluded by PLIPNAG.61: 3 residues within 4Å:- Chain I: N.103, R.113, G.114
Ligand excluded by PLIPNAG.62: 3 residues within 4Å:- Chain J: S.109, E.110, N.114
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain J: E.123, N.126, Y.127
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Melzi, E. et al., Priming HIV Envelope V2 Apex-directed broadly neutralizing antibody responses with protein or mRNA immunogens. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV-1 Envelope ApexGT5 gp120: AEI
HIV-1 Envelope ApexGT5 gp41: BFJ
RM20A3 Fab Heavy Chain: CGK
RM20A3 Fab Light Chain: DHL
GT5-d42.16 Fab Heavy Chain: M
GT5-d42.16 Fab Light Chain: N - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
EB
BF
DJ
FC
JG
MK
OD
KH
NL
PM
HN
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 41 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Melzi, E. et al., Priming HIV Envelope V2 Apex-directed broadly neutralizing antibody responses with protein or mRNA immunogens. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV-1 Envelope ApexGT5 gp120: AEI
HIV-1 Envelope ApexGT5 gp41: BFJ
RM20A3 Fab Heavy Chain: CGK
RM20A3 Fab Light Chain: DHL
GT5-d42.16 Fab Heavy Chain: M
GT5-d42.16 Fab Light Chain: N - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
EB
BF
DJ
FC
JG
MK
OD
KH
NL
PM
HN
L